Nuvation Bio Inc. Proceeds from Sale and Maturity of Held-to-maturity Securities
Nuvation Bio Inc. (NUVB) reported Proceeds from Sale and Maturity of Held-to-maturity Securities of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities · last filed 2022-02-28
- Nuvation Bio Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2020-12-31 was $0.00.
- Nuvation Bio Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2020 was $2.51M.
| Period end | Proceeds from Sale and Maturity of Held-to-maturity Securities 3 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 9 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 12 month |
|---|---|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.51M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $2.51M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |